Amgen Inc.
AMGN
Rank in Stocks
#73
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California,... Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Share Price
$432.40
Last synced: 2026-10-16
Market Cap
$233.77B
Change (1 day)
-0.38%
Change (1 year)
44.71%
Country
US
Trade Amgen Inc. (AMGN)
Category
Healthcare
Operating Margin for Amgen Inc. (AMGN)
Operating Margin as of October 2026 TTM: 33.18%
According to Amgen Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 33.18%. At the end of 2024 the company had an Operating Margin of 21.71%.
Operating Margin history for Amgen Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 33.18% | -18.11% |
| 2025 | 40.52% | 86.64% |
| 2024 | 21.71% | -22.49% |
| 2023 | 28.01% | -22.92% |
| 2022 | 36.34% | 23.61% |
| 2021 | 29.40% | -18.22% |
| 2020 | 35.95% | -13.19% |
| 2019 | 41.41% | -4.19% |
| 2018 | 43.22% | -0.99% |
| 2017 | 43.65% | 2.46% |
| 2016 | 42.60% | 8.95% |
| 2015 | 39.10% | 26.70% |
| 2014 | 30.86% | -1.75% |
| 2013 | 31.41% | -2.76% |
| 2012 | 32.30% | 16.73% |
| 2011 | 27.67% | -24.89% |
| 2010 | 36.84% | -2.02% |
| 2009 | 37.60% | 8.20% |
| 2008 | 34.75% | 28.99% |
| 2007 | 26.94% | 0.11% |
| 2006 | 26.91% | -31.00% |
| 2005 | 39.00% | 22.91% |
| 2004 | 31.73% | -14.22% |
| 2003 | 36.99% | -360.31% |
| 2002 | -14.21% | -137.27% |
| 2001 | 38.13% | -3.88% |
| 2000 | 39.67% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 49.72% | -98.50% |
US
|
|
| 25.70% | -99.23% |
US
|
|
| 29.32% | -99.12% |
US
|
|
| 26.59% | -99.20% |
CH
|
|
| 16.65% | -99.50% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.